Status: retired, Not sufficiently defined by necessary conditions definition status. Date: 28-Nov 2018. Module: SNOMED CT United Kingdom drug extension module
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 109554601000001113 | Bendroflumethiazide 2.5mg / Potassium chloride 630mg (potassium 8.4mmol) modified-release tablets (product) | en | Fully specified name | Active | Only initial character case insensitive | SNOMED CT United Kingdom drug extension module |
| 109554701000001115 | Bendroflumethiazide 2.5mg / Potassium chloride 630mg (potassium 8.4mmol) modified-release tablets | en | Synonym | Active | Only initial character case insensitive | SNOMED CT United Kingdom drug extension module |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Bendroflumethiazide 2.5mg / Potassium chloride 630mg (potassium 8.4mmol) modified-release tablets | Is a | Product containing bendroflumethiazide and potassium | false | Inferred relationship | Existential restriction modifier | ||
| Bendroflumethiazide 2.5mg / Potassium chloride 630mg (potassium 8.4mmol) modified-release tablets | Has active ingredient | Potassium | false | Inferred relationship | Existential restriction modifier | ||
| Bendroflumethiazide 2.5mg / Potassium chloride 630mg (potassium 8.4mmol) modified-release tablets | Has active ingredient | Bendroflumethiazide | false | Inferred relationship | Existential restriction modifier | ||
| Bendroflumethiazide 2.5mg / Potassium chloride 630mg (potassium 8.4mmol) modified-release tablets | VMP prescribing status (attribute) | VMP valid as a prescribable product | false | Inferred relationship | Existential restriction modifier | ||
| Bendroflumethiazide 2.5mg / Potassium chloride 630mg (potassium 8.4mmol) modified-release tablets | VMP non-availability indicator | Not available | false | Inferred relationship | Existential restriction modifier | ||
| Bendroflumethiazide 2.5mg / Potassium chloride 630mg (potassium 8.4mmol) modified-release tablets | Has dispensed dose form | Modified-release oral tablet | false | Inferred relationship | Existential restriction modifier | ||
| Bendroflumethiazide 2.5mg / Potassium chloride 630mg (potassium 8.4mmol) modified-release tablets | Has specific active ingredient | Bendroflumethiazide | false | Inferred relationship | Existential restriction modifier | ||
| Bendroflumethiazide 2.5mg / Potassium chloride 630mg (potassium 8.4mmol) modified-release tablets | Has specific active ingredient | Potassium chloride | false | Inferred relationship | Existential restriction modifier | ||
| Bendroflumethiazide 2.5mg / Potassium chloride 630mg (potassium 8.4mmol) modified-release tablets | Is a | Virtual medicinal product | false | Inferred relationship | Existential restriction modifier |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Bendroflumethiazide 2.5mg / Potassium 8.4mmol modified-release tablets 100 tablet | Has VMP | False | Bendroflumethiazide 2.5mg / Potassium chloride 630mg (potassium 8.4mmol) modified-release tablets | Inferred relationship | Existential restriction modifier | |
| Neo-Naclex-K modified-release tablets (Goldshield Healthcare Ltd) | Is a | False | Bendroflumethiazide 2.5mg / Potassium chloride 630mg (potassium 8.4mmol) modified-release tablets | Inferred relationship | Existential restriction modifier |
This concept is not in any reference sets
FHIR